Completed PHASE4 INTERVENTIONAL 2-arm NCT00353834

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes

Sponsor: Amylin Pharmaceuticals, LLC.

Conditions Type 2 Diabetes Mellitus

Interventions Exenatide Glargine Insulin

Updated 8 times since 2017 Last updated: Dec 7, 2017 Started: Aug 31, 2006 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00353834, this PHASE4 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Amylin Pharmaceuticals, LLC., it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2018 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Jan 2018 [monthly]

Completed PHASE4

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
Joslin Diabetes Center

Data source: Joslin Diabetes Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States